Drugs moving into the clinic: 23
The latest in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
industry regulators.
| Sponsor | Name | Indication | Mechanism |
|---|---|---|---|
| Nicox | Undisclosed | Cardiovascular - anti hypertension | Target undisclosed but Nicox specialise in NO-donating drugs |
| Xoma | XOMA 052 | Metabolic - Type II diabetes | monoclonal antibody targeting Interleukin-1 beta (IL-1 beta) |
| Arena Pharma- ceuticals | APD791 | Cardiovascular - arterial thrombo-embolic diseases | Selective inverse inhibitor of the 5-HT2A serotonin receptor |
| Affiris | Affitope AD01 | CNS - Alzheimer's | Only combats the disease-causing beta-amyloid (after it has separated into the brain fluid), irrespective of whether it is still present in the brain fluid, or has formed plaque deposits. |
| Cougar Biotechnology | CB3304 | Oncology - relapsed or refractory multiple myeloma | alkaloid derived from opium to inhibit microtubule dynamics, block cell division (mitosis) and cause apoptosis. |
| Quigley Pharma | QR-449 | Metabolic Syndrome | Broad spectrum compound that modifies levels of pro-inflammatory cytokines and other factors, e.g. Interleukin-6 (IL- 6) |
| NeuroSearch & Abbott | ABT-560 | CNS | neuronal nicotinic receptor (NNR) modulator |
| Medivation | MDV3100 | Oncology - hormone-refractory prostate cancer | Androgen receptor (AR) inhibitor |
| Athersys | ATHX-105 | Metabolism - obesity | Stimulates the 5HT2c serotonin receptor without activating 5HT2b - which can cause cardivascular side effects |
| Targacept | TC-5619 | CNS - Schizophrenia, Cognitive Impairment, Inflammation | Neuronal nicotinic receptor (NNR) modulator - alpha7 subtype |
| Icagen | ICA-105665 | CNS - epilepsy | activates subtypes of KCNQ ion channels |
| Novavax | undisclosed | Anti-infectives and Vaccines - flu | virus-like particle ("VLP") based pandemic influenza vaccine (H5N1 clade 2) |
